CTLA4 is limited to the activated T cells and Tregs, and CTLA4 impedes tumor progression by depleting Tregs and modulating Treg suppressive activity (33), and therefore, anti-CTLA4 antibodies are indicated in patients with high risk scores. This evidence concerns the gene CTLA4 and neoplasm.